Skip to main content
SpringerLink
Log in

Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The androgen receptor (AR) is a transcription factor mediating the action of androgens. The AR gene is localized on chromosome X and it contains a series of CAG trinucleotide repeats. The length of the CAG repeats varies among individuals and this polymorphism is believed to be related to AR transcriptional activity. Studies have shown that fewer CAG repeats are associated with an increased risk as well as more aggressive forms of prostate cancer. Although AR is expressed in breast cancer and the impact of androgen and AR on breast cancer has been recognized, the role of the CAG repeats in breast cancer remains unknown. In this study, we measured the CAG repeats in breast cancer tissue using a PCR-based method. Of the 133 patients with primary breast cancer, 102 were heterozygous and 31 were homozygous. The mean CAG repeat number for homozygous women was 21; for heterozygous women the repeat number mean was 20 for the short allele and 24 for the long allele. The length of CAG repeats either in one allele or in both alleles was inversely correlated with the histological grade of breast cancer (r = −0.23 or −0.26, respectively, p<0.05). An association between positive lymph nodes and fewer CAG repeats in both alleles was also suggested (p = 0.06). Furthermore, survival analysis indicated that the total number of CAG repeats in both alleles was associated with patient overall survival. With every CAG repeat increase, there was a 6% reduction in the risk of death (RR = 0.94, p = 0.03). The association remained significant after controlling for the homozygous and heterozygous status (RR = 0.92, p = 0.01). The association became no longer significant when clinical and pathological variables were adjusted in the analysis but this could be due to the reduction of sample size in the multivariate analysis. CAG heterozygosity and difference in number of CAG repeats between the two alleles were not associated with either disease features or patient survival. Our results suggest that longer CAG repeats may occur more frequently in less aggressive cancer and that the CAG repeats may play a role in breast cancer progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Quigley CA, De Bellis A, Marschke KB, El-Awady, MK, Wilson EM, French FS: Androgen receptor defects: historical, clinical and molecular perspectives. Endocr Rev 16: 271–321, 1995

    Google Scholar 

  2. Rundlett SE, Wu XP, Miesfeld RL: Functional characterization of the androgen receptor confirms that the molecular basis of androgen action is transcriptional regulation. Mol Endocrinol 4: 708–714, 1990

    Google Scholar 

  3. Gerber HP, Seipel K, Georgiev O, Hofferer M, Hug M, Rusconi S, Schaffner W: Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science 263: 808–811, 1994

    Google Scholar 

  4. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94: 3320–3323, 1997.

    Google Scholar 

  5. Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA, Ostrander EA: Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 57: 1194–1198, 1997

    Google Scholar 

  6. Ingles SA, Ross RK, YuMC, Irvine RA, La Pera G, Haile RW, Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89: 166–170, 1997

    Google Scholar 

  7. Trapman J, Brinkmann AO: The androgen receptor in prostate cancer. Path Res Pract 192: 752–760, 1996

    Google Scholar 

  8. Secreto G, Zumoff B: Abnormal production of androgens in women with breast cancer. Anticancer Res 14: 2113–2118, 1994

    Google Scholar 

  9. Lea OA, Kvinnsland S, Thorsen T: Improved measurement of androgen receptors in human breast cancer. Cancer Res 49: 7162–7167, 1989

    Google Scholar 

  10. de Winter JAR, Trapman J, Vermey M, Mulder E, Zegers ND, van der Kwast TH. Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem 39: 927–936, 1991

    Google Scholar 

  11. Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S: Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 18: 112–118, 1992

    Google Scholar 

  12. Kuenen-Boumeester V, van der Kwast TH, van Putten WLJ, Claassen C, van Ooijen B, Henzen-Logmans SC: Immunohistochemical determination of androgen receptors in relation to estrogen and progesterone receptors in female breast cancer. Int J Cancer 52: 581–584, 1992

    Google Scholar 

  13. Pritchard KI, Sutherland DJA: The use of endocrine therapy. Hematol Oncol Clin North Am 3: 765–805, 1989

    Google Scholar 

  14. Hyman B, Muss MD: Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 21: 15–26, 1992

    Google Scholar 

  15. Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajino R, Pisani P, Panico S, Secreto G: Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 88: 291–296, 1996

    Google Scholar 

  16. Dorgan JF, Longcope C, Stephenson HE Jr, Falk RT, Miller R, Franz C, Kahle L, Campbell WS, Tangrea JA, Schatzkin A: Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarker Prev 5: 533–539, 1996

    Google Scholar 

  17. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri R, Speizer FE: Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90: 1292–1299, 1998

    Google Scholar 

  18. Yu H, Diamandis EP, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M, Croce CM: Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 40: 171–178, 1996

    Google Scholar 

  19. Bharaj BS, Vassilikos EJK, Diamandis EP: Rapid and accurate determination of (CAG)n repeats in the androgen receptor gene using polymerase chain reaction and automated fragment analysis. Clin Biochem 32: 327–332, 1999

    Google Scholar 

  20. Irvine RA, YuMC, Ross RK, Coetzee GA: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55: 1937–1940, 1995

    Google Scholar 

  21. Hardy DO, Scher HI, Bogenreider T, Sabbatini P, Zhang ZF, Nanus DM, Catterall JF: Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Meta 81: 4400–4405, 1996

    Google Scholar 

  22. Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M: Modification of BRCA1-associated breast cancer risk by the polymorphic androgen receptor CAG repeat. Am J Hum Genet 64: 1371–1377, 1999

    Google Scholar 

  23. Spurdle AB, Dite GS, Chen X, Mayne CJ, SoutheyMC, Batten LE, Chy H, Trute L, McCredie MR, Giles GG, Armes J, Venter DJ, Hopper JL, Chevevix-Trench G: Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years. J Natl Cancer Inst 91: 961–966, 1999

    Google Scholar 

  24. Hakimi JM, Schoenberg MP, Rondinelli RH, Piantadosi S, Barrack ER: Androgen receptor variants with short glutamanine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 3: 1599–1608, 1997

    Google Scholar 

  25. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Molec Biol 52: 459–467, 1995

    Google Scholar 

  26. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474–5478, 1994

    Google Scholar 

  27. Reinikainen P, Palvimo JJ, Janne OA: Effects of mitogens on androgen receptor-mediated transactivation. Endocrinology 137: 4351–4357, 1996

    Google Scholar 

  28. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z: Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58: 4640–4645, 1998

    Google Scholar 

  29. Ignar-Trowbridge DM, Pimentel M, Parker MG, McLachlan JA, Korach KS. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 137: 1735–1744, 1996

    Google Scholar 

  30. Rasmussen AA, Cullen KJ: Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Cancer Res Treat 47: 219–233, 1998

    Google Scholar 

  31. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393–1396, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Louisiana State University Medical Centre, Shreveport, LA, USA

    He Yu

  2. Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada

    Bhupinder Bharaj, Evyenia J.K. Vassilikos & Eleftherios P. Diamandis

  3. Department of Gynecologic Oncology, Institute of Obstetrics/Gynecology, University of Turin, Turin, Italy

    Maurizia Giai

  4. Department of Laboratory Medicine and Pathobiology, Banting Institute, University of Toronto, Toronto, Ontario, Canada

    Eleftherios P. Diamandis

Authors
  1. He Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bhupinder Bharaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Evyenia J.K. Vassilikos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maurizia Giai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eleftherios P. Diamandis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, H., Bharaj, B., Vassilikos, E.J. et al. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Res Treat 59, 153–161 (2000). https://doi.org/10.1023/A:1006356502820

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006356502820

Search

Navigation